Semaglutide and Neovascular Age-Related Macular Degeneration among Adults with Type 2 Diabetes: An Observational Health Data Sciences and Informatics Network Study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cai Cindy X, Toy Brian, Martin Benjamin, Fan Ruochong, Westlund Erik, Tran Diep, Nishimura Akihiko, Lee Haeun, Leng Theodore, Nagy Paul, Mathioudakis Nestoras, Zhang Linying, Hribar Michelle, Chen Aiyin, Armbrust Karen, Goetz Kerry, Baxter Sally, Boland Michael V, Brown Eric N, Tsui Edmund, Barkmeier Andrew J, Wang Sophia, Mehta Nitish, Stocking Jacqueline C, O'Keefe Ghazala, Lee Cecilia S, Payne Philip R O, O'Brien William J, DuVall Scott, Alshammari Thamir, Falconer Thomas, Dorr David A, Humes Izabelle, McCoy David, Adibuzzaman Mohammed, Mahmood Rumel, Morgan-Cooper Hannah, Desai Priya, Kothari Shikha Yashwant, Sena Anthony, Blacketer Clair, Ostropolets Anna, Shoaibi Azza, Rao Gowtham, Hripcsak George, Ryan Patrick, Suchard Marc A
Аннотация
DESIGN: Retrospective study across 12 databases in the Observational Health Data Sciences and Informatics network from December 1, 2017, through December 31, 2024.
PARTICIPANTS: Adults with type 2 diabetes (T2D) taking semaglutide, other glucagon-like peptide-1 receptor agonists (GLP-1RAs; e.g., dulaglutide or exenatide), or non-GLP-1RAs (e.g., empagliflozin, sitagliptin, or glipizide).
METHODS: The association between semaglutide use and NVAMD was assessed using 2 approaches: an active-comparator cohort design and a self-controlled case series analysis. The former used propensity score-adjusted Cox proportional hazards models to estimate hazard ratios (HRs). The latter used conditional Poisson regression models to estimate incidence rate ratios (IRRs). A random-effects meta-analysis was used to generate network-wide HR and IRR estimates.
MAIN OUTCOME MEASURES: Two definitions of NVAMD, one based on condition codes alone (NVAMD-C) and one based on condition codes and procedures (NVAMD-CP).
RESULTS: A total of 227 971 new users of semaglutide were included in the study. The risk of NVAMD among semaglutide users was similar to that of users of dulaglutide (NVAMD-C: HR, 0.57; 95% CI, 0.21-1.57; P = 0.28; NVAMD-CP: HR, 0.25; 95% CI, 0.05-1.27; P = 0.10), empagliflozin (NVAMD-C: HR, 0.98; 95% CI, 0.54-1.79; P = 0.94; NVAMD-CP: HR, 0.79; 95% CI, 0.38-1.64; P = 0.52), sitagliptin (NVAMD-C: HR, 2.08; 95% CI, 0.90-4.83; P = 0.09; NVAMD-CP: HR, 1.80; 95% CI, 0.55-5.86; P = 0.33), and glipizide (NVAMD-C: HR, 0.83; 95% CI, 0.35-2.02; P = 0.69; NVAMD-CP: HR, 0.50; 95% CI, 0.21-1.19; P = 0.12). No evidence was found of increased or decreased risk for NVAMD associated with semaglutide exposure (NVAMD-C: IRR, 0.92; 95% CI, 0.67-1.26; P = 0.60; NVAMD-CP: IRR, 1.02; 95% CI, 0.76-1.36; P = 0.92) nor with any of the other GLP-1RAs or non-GLP-1RAs.
CONCLUSIONS: We detected no differences in the risk of NVAMD associated with semaglutide use among adults with T2D.
FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.